Health
Researchers develop ultrapotent miniproteins that target SARS-CoV-2 receptor-binding domain – News-Medical.Net
Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the…
Last September, researchers at the University of Washington, USA, reported the development of computer-designed small proteins – ‘miniproteins’ – that can target the receptor-binding domain (RBD) on the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic.
This work was published in the journal Science, claiming the lead antiviral miniprotein candidate, named LCB1, which exhibited better protective…
-
Noosa News15 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News20 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News22 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common
-
Noosa News14 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash